Galectin‐3 in Heart Failure: More Answers or More Questions?
Open Access
- 26 September 2012
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 1 (5) , e004374
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Galectin-3 in Ambulatory Patients With Heart FailureCirculation: Heart Failure, 2012
- Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and SurvivalThe American Journal of Cardiology, 2011
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fractionAnnals of Medicine, 2010
- Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF studyClinical Research in Cardiology, 2010
- Galectins: regulators of acute and chronic inflammationAnnals of the New York Academy of Sciences, 2010
- Galectin-3: A Novel Mediator of Heart Failure Development and ProgressionEuropean Journal of Heart Failure, 2009
- N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectinAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Biomarkers in Heart FailureNew England Journal of Medicine, 2008
- Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac DysfunctionCirculation, 2004
- The defintion of heart failureEuropean Heart Journal, 1983